Menu
Search
|

Menu

Close
X

DURECT Corp DRRX.OQ (NASDAQ Stock Exchange Global Market)

0.83 USD
+0.00 (+0.00%)
As of Nov 20
chart
Previous Close 0.83
Open 0.90
Volume 75,911
3m Avg Volume 92,465
Today’s High 0.90
Today’s Low 0.82
52 Week High 2.55
52 Week Low 0.82
Shares Outstanding (mil) 162.06
Market Capitalization (mil) 139.34
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
15
FY17
49
FY16
14
FY15
19
EPS (USD)
FY18
-0.114
FY17
-0.032
FY16
-0.259
FY15
-0.191
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
4.04
20.58
Price to Book (MRQ)
vs sector
5.34
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
76.22
13.84
LT Debt to Equity (MRQ)
vs sector
36.41
9.93
Return on Investment (TTM)
vs sector
-29.35
13.58
Return on Equity (TTM)
vs sector
-54.18
15.11

EXECUTIVE LEADERSHIP

Felix Theeuwes
Chairman, Chief Scientific Officer, Since 1998
Salary: $277,452.00
Bonus: --
James Brown
President, Chief Executive Officer and Director, Since 1998
Salary: $470,385.00
Bonus: --
Michael Arenberg
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Judy Joice
Senior Vice President - Operations and Corporate Quality Assurance, Since 2014
Salary: $275,782.00
Bonus: --
Myriam Theeuwes
Senior Vice President - Clinical Development, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10260 Bubb Rd
CUPERTINO   CA   95014-4166

Phone: +1408.7771417

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.

SPONSORED STORIES